|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Developed technology - on-body infusor | ||||||||||||||||||||
| IPR&D - ReadyFlow Formulation | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Financing liability — current | ||||||||||||||||||||
| Senior convertible notes - current | ||||||||||||||||||||
| Liability for sale of future royalties - current | ||||||||||||||||||||
| Contingent consideration - current | ||||||||||||||||||||
| Financing liability - current | ||||||||||||||||||||
| Deferred revenue — current | ||||||||||||||||||||
| Recognized loss on purchase commitments — current | ||||||||||||||||||||
| Midcap credit facility - current | ||||||||||||||||||||
| Recognized loss on purchase commitments - current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Liability for sale of future royalties - long term | ||||||||||||||||||||
| Financing liability - long term | ||||||||||||||||||||
| Deferred revenue — long term | ||||||||||||||||||||
| Recognized loss on purchase commitments — long term | ||||||||||||||||||||
| Operating lease liability | ||||||||||||||||||||
| Contingent consideration - long term | ||||||||||||||||||||
| Milestone liabilities | ||||||||||||||||||||
| Financing lease liability | ||||||||||||||||||||
| Midcap credit facility - long term | ||||||||||||||||||||
| Mann Group convertible note | ||||||||||||||||||||
| Accrued interest - Mann Group convertible note | ||||||||||||||||||||
| Term loan | ||||||||||||||||||||
| Senior convertible notes | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' deficit: | ||||||||||||||||||||
| Common stock, $0.01 par value - 800,000,000 shares authorized; 309,911,682 and 307,832,587 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' deficit | ||||||||||||||||||||
| Total liabilities and stockholders' deficit | ||||||||||||||||||||
Loading...
